Mitigate Japan's Drug Loss With Model‐Informed Drug Development
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Yasuhiko Imai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Certara GK, Tokyo, Japan. Hauptthemen laut MEDLINE: Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
‘Drug loss’ in Japan refers to drugs that have been approved and marketed overseas but haven't been developed, submitted, or approved in Japan. A comprehensive Model‐Informed Drug Development (MIDD) strategy, enhanced with artificial intelligence/machine learning, can minimize drug loss. Continued pharmaceutical industry and regulatory commitment and collaboration in applying MIDD will facilitate Japanese patients' access to essential medicines and solidify Japan's role in global pharmaceutical advancement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Certara GK, Tokyo, Japan.
- Certara USA, Radnor, Pennsylvania, USA.
ORCID-Profile: Emi Akatsu, Suzanne K Minton
Zitieren
APA
Imai, Y., Akatsu, E., & Minton, S. K. (2025). Mitigate Japan's Drug Loss With Model‐Informed Drug Development. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70126
Vancouver
Imai Y, Akatsu E, Minton SK. Mitigate Japan's Drug Loss With Model‐Informed Drug Development. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70126
BibTeX
@article{Imai2025,
author = {Imai, Yasuhiko and Akatsu, Emi and Minton, Suzanne K},
title = {Mitigate Japan's Drug Loss With Model‐Informed Drug Development},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70126}
}
EUVIMED